UNSPSC 51241538: Naphazoline/zinc sulfate

This classification denotes a combination drug defined by the U.S. Department of Veterans Affairs in its (VA's) National Drug File (NDF), which falls under VA Drug Class OP800. This VA Drug Class (OP800) classifies this compound as belonging to the group DECONGESTANTS, TOPICAL OPHTHALMIC.

UNSPSC 51241538 Naphazoline/zinc sulfate (Commodity) encompasses ophthalmic pharmaceutical products procured through cooperative purchasing vehicles by state and local health agencies. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) is actively soliciting manufacturers of generic multi-source pharmaceuticals and over-the-counter products, including this and related eye-care formulations, for supply agreements with state and local government facilities across participating jurisdictions. The scope of work requires vendors to supply products through three authorized wholesalers—AmerisourceBergen Drug Corporation (Cencara), Cardinal Health 110 and 112, and Morris & Dickson Co., LLC—with detailed product information including National Drug Codes (NDC), SKUs, UPCs, generic descriptions, strength, dosage form, trade names, packaging configurations, and manufacturing locations. Vendors must certify compliance with current Good Manufacturing Practices (cGMP) and the Drug Supply Chain Security Act (DSCSA), maintain contractual relationships with at least two of the three authorized wholesalers with chargeback systems in place, and demonstrate pricing flexibility through flat price, net price formats (NF30, NF60, NF90), or WAC-minus pricing structures. All products must comply with FDA requirements and possess expiration dates of at least one year from manufacture with a minimum six-month shelf life. Vendors must carry workers' compensation, commercial general liability of $5,000,000 per occurrence, network security and privacy liability of $2,000,000, and professional liability of $2,000,000.

MMCAP represents the primary recent activity under this code, with participation spanning Minnesota and Oregon. The Minnesota Department of Administration's Office of State Procurement issued RFP S1070000015802 on January 20, 2026, with proposals due March 26, 2026; the RFP establishes multiple contracts for generic pharmaceuticals with awarded vendors to be provided to authorized wholesalers by May 15, 2026, and resulting agreements effective July 1, 2026. Evaluation weights 75 percent to price competitiveness, 10 percent to fixed pricing, and the remainder to administrative compliance, EDI capability, and administrative fee agreement. All products must be available in the marketplace by May 15, 2026, and the contract term runs two years for new responders with optional extensions, while incumbent amendments align with existing expiration dates through June 30, 2028. Vendors must pay a 3 percent administrative fee on all contract purchases and comply with performance penalties ranging from $200 to $1,500 per violation.